See more : BASF SE (BAS.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Elutia Inc. (ELUT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Elutia Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Compagnie Internationale pour la Communication (CIE.SW) Income Statement Analysis – Financial Results
- Sorrento Therapeutics, Inc. (SRNEQ) Income Statement Analysis – Financial Results
- Caisse Régionale de Crédit Agricole Mutuel de La Touraine et du Poitou Société Coopérative (CRTO.PA) Income Statement Analysis – Financial Results
- Paradise Entertainment Limited (PDSSF) Income Statement Analysis – Financial Results
- Platinex Inc. (PANXF) Income Statement Analysis – Financial Results
Elutia Inc. (ELUT)
About Elutia Inc.
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 24.75M | 23.85M | 47.39M | 42.68M | 42.90M | 39.04M |
| Cost of Revenue | 13.69M | 12.21M | 28.37M | 22.12M | 23.13M | 23.09M |
| Gross Profit | 11.05M | 11.64M | 19.02M | 20.56M | 19.77M | 15.95M |
| Gross Profit Ratio | 44.67% | 48.80% | 40.14% | 48.17% | 46.08% | 40.84% |
| Research & Development | 4.40M | 7.73M | 9.27M | 4.08M | 2.40M | 2.48M |
| General & Administrative | 14.10M | 16.05M | 13.69M | 10.64M | 0.00 | 0.00 |
| Selling & Marketing | 13.09M | 17.85M | 18.83M | 17.57M | 0.00 | 0.00 |
| SG&A | 27.19M | 33.90M | 32.79M | 30.08M | 25.78M | 21.69M |
| Other Expenses | 9.99M | 4.16M | 3.58M | -2.57M | 0.00 | 0.00 |
| Operating Expenses | 41.58M | 41.63M | 42.05M | 34.16M | 28.18M | 24.17M |
| Cost & Expenses | 55.27M | 53.84M | 70.42M | 56.28M | 51.31M | 47.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.80M | 5.12M | 5.32M | 5.63M | 5.38M | 5.52M |
| Depreciation & Amortization | 3.51M | 3.57M | 3.73M | 3.86M | 3.90M | 3.80M |
| EBITDA | -31.92M | -27.46M | -15.72M | -12.30M | -2.63M | -2.22M |
| EBITDA Ratio | -128.98% | -110.79% | -40.73% | -22.81% | -10.51% | -11.32% |
| Operating Income | -30.53M | -29.99M | -23.03M | -13.60M | -8.41M | -8.22M |
| Operating Income Ratio | -123.36% | -125.75% | -48.60% | -31.86% | -19.60% | -21.06% |
| Total Other Income/Expenses | -10.70M | -6.16M | -1.75M | -8.20M | -3.50M | -3.32M |
| Income Before Tax | -41.22M | -36.15M | -24.78M | -21.80M | -11.91M | -11.54M |
| Income Before Tax Ratio | -166.58% | -151.57% | -52.28% | -51.07% | -27.76% | -29.56% |
| Income Tax Expense | 28.00K | 34.00K | 55.00K | 26.00K | 30.00K | 26.00K |
| Net Income | -37.66M | -32.90M | -24.83M | -21.83M | -11.94M | -11.57M |
| Net Income Ratio | -152.18% | -137.94% | -52.40% | -51.13% | -27.83% | -29.63% |
| EPS | -2.07 | -2.38 | -2.38 | -2.13 | -1.12 | -1.08 |
| EPS Diluted | -2.07 | -2.38 | -2.38 | -2.13 | -1.12 | -1.08 |
| Weighted Avg Shares Out | 18.16M | 13.83M | 10.44M | 10.23M | 10.67M | 10.67M |
| Weighted Avg Shares Out (Dil) | 18.16M | 13.83M | 10.44M | 10.23M | 10.67M | 10.67M |
3 Best Breakout Stocks Worth a Buy for Attractive Returns
Elutia Announces $13.26 Million Registered Direct Offering
Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
Elutia, Inc. (ELUT) Q1 2024 Earnings Call Transcript
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
Elutia, Inc. (ELUT) Q4 2023 Earnings Call Transcript
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
Elutia Regains Compliance with Nasdaq Listing Requirements
Elutia Inc. (ELUT) Upgraded to Buy: Here's Why
Source: https://incomestatements.info
Category: Stock Reports